Intake of chlorogenic acid and trigonelline reduce postprandial glucose concentrations during an oral glucose tolerance test relative to placebo.
ID
Bron
Verkorte titel
Aandoening
Diabetes Mellitus type 2 (DM type II)
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Glucose and insulin concentrations in blood
Achtergrond van het onderzoek
High coffee consumption is associated with a lower risk of type 2 diabetes. Similar associations are observed for caffeinated and decaffeinated coffee, suggesting that coffee components other than caffeine have beneficial effects on glucose homeostasis. Chlorogenic acid and trigonelline are major components in coffee and may be partly responsible for improved glucose tolerance following coffee consumption. The objective of this study is to test whether chlorogenic acid and trigonelline ingestion acutely reduce postprandial glucose concentrations in humans. The study is a randomized cross-over trial in 20 overweight men including 4 treatments: decaffeinated coffee, chlorogenic acid, trigonelline, and placebo. Acute effects on glucose and insulin responses following an oral glucose tolerance test will be examined.
Doel van het onderzoek
Intake of chlorogenic acid and trigonelline reduce postprandial glucose concentrations during an oral glucose tolerance test relative to placebo.
Onderzoeksproduct en/of interventie
All participants will receive four treatments in random order, on four different days:
1. Decaffeinated coffee;
2. Chlorogenic acid.
3. Trigonelline.
4. Mannitol (placebo).
All treatments will be ingested before an oral glucose tolerance test. Blood samples will be taken on 7 occasions on each study day. Treatments will be double blind, except for the decaffeinated coffee treatment.
Publiek
Margreet R. Olthof
De Boelelaan 1085
Amsterdam 1081 HV
The Netherlands
+31 205982522
margreet.olthof@falw.vu.nl
Wetenschappelijk
Margreet R. Olthof
De Boelelaan 1085
Amsterdam 1081 HV
The Netherlands
+31 205982522
margreet.olthof@falw.vu.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Apparently healthy males;
Acute effects of coffee and major coffee components on glucagon-like peptide 1 response and glucose tolerance in humans;
2. Age at screening: 18 years and above;
3. Body mass index (BMI) between 25.0 and 35.0 kg/m2;
4. Regular coffee consumer;
5. Willing to restrict coffee consumption during the study to max. 1 cup per day;
6. Voluntary participation;
7. Willing not to be blood or plasmaferese donor from 4 weeks before the start of the study until the end of study.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Women;
2. Smokers;
3. Diabetics;
4. Blood sampling is considered too difficult (assessed during pre-study screening);
5. Any chronic or acute disease;
6. Hypertension criteria for moderate hypertension WHO 2003;
7. Medical history or surgical events known to interfere with the study;
8. Alcohol consumption > 28 consumptions per week;
9. Self reported weight loss or gain > 2 kg in the month prior to screening;
10. Any special diet;
11. Participation in any other intervention trial up to 3 months before and during this study;
12. Use of medication known to interfere with the study outcome;
13. Exercising more than 4 hours vigorously per week.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1020 |
| NTR-old | NTR1051 |
| Ander register | : 2006.11.020/2946308 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |